Temozolomide - Just a Radiosensitizer?

Front Oncol

Department of Neurology, Sozialstiftung, Bamberg, Germany.

Published: June 2022

Radiation concomitant with the DNA methylating drug temozolomide (TMZ) is the gold standard in the treatment of glioblastoma. In this adjuvant setting, TMZ is regarded to be a radiation sensitizer. However, similar to ionising radiation, TMZ induces DNA double-strand breaks and is itself a potent trigger of apoptosis, cellular senescence and autophagy, suggesting that radiation and TMZ act independently. Although cell culture experiments yielded heterogeneous results, some data indicate that the cytotoxic effect of radiation was only enhanced when TMZ was given before radiation treatment. Based on the molecular mechanism of action of TMZ, the importance of specific TMZ and radiation-induced DNA lesions, their repair as well as their interactions, possible scenarios for an additive or synergistic effect of TMZ and radiation are discussed, and suggestions for an optimal timing of radio-chemical treatments are proposed.

Download full-text PDF

Source
http://www.ncbi.nlm.nih.gov/pmc/articles/PMC9246413PMC
http://dx.doi.org/10.3389/fonc.2022.912821DOI Listing

Publication Analysis

Top Keywords

tmz
8
radiation tmz
8
tmz radiation
8
radiation
7
temozolomide radiosensitizer?
4
radiosensitizer? radiation
4
radiation concomitant
4
concomitant dna
4
dna methylating
4
methylating drug
4

Similar Publications

Want AI Summaries of new PubMed Abstracts delivered to your In-box?

Enter search terms and have AI summaries delivered each week - change queries or unsubscribe any time!